Radical Gastrectomy Within Enhanced Recovery Programs(ERAS): a Prospective Randomized Controlled Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-20

Study Completion Date

2019-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, single-center, randomized controlled trial. The study protocol was approved by the Ethics Committee at the First Hospital of Jilin University.ERAS is combined with the laprascopic gastrectomy to assess the efficacy and safety in patients with advanced gastric carcinoma.The hospitalized patients were randomly divided into ERAS group and conventional pathway group . Inter-group differences were evaluated for clinical recovery index, economic indicators, length of hospital stay, 3 years to 5 years long-term survival, etc.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enhanced Recovery After Surgery (ERAS) on Laparoscopy-assisted Distal Gastrectomy

NCT03016026

Stomach Neoplasms

UNKNOWN PHASE2

The Impact of Enhanced Recovery After Surgery (ERAS) Program on Clinical and Immunological Outcomes for Minimally-invasive Gastrectomy

NCT03160924

Enhanced Recovery After Surgery for Laparoscopic Gastrectomy for Patients With Gastric Cancer

UNKNOWN PHASE3

Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer

NCT07029269

Gastric Adenocarcinoma Laparoscopic Gastrectomy Complications

RECRUITING PHASE3

ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer

NCT06489288

Gastric Cancer ERAS Laparoscopic Gastrectomy

ACTIVE_NOT_RECRUITING NA

Compliance to ERAS After Gastric Surgery

NCT01653496

Stomach Neoplasms

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrostomy Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ERAS group

Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.

Group Type EXPERIMENTAL

ERAS

Intervention Type PROCEDURE

optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization

conventional pathway group

The conventional pathway group received conventional care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ERAS

optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) A preoperative cancer stage of T2, T3, T4, Any N, M0 without digestive obstruction confirmed by whole body CT scan, which could be treated with laparoscopic gastrectomy; (2) age 18-75 years; (3) pathologic confirmation of gastric adenocarcinoma by endoscopic biopsy; (4) normal hematological, renal, hepatic, and cardiac parameters, ASA score \< III without severe systemic disease; and (5) no history of treatment with neoadjuvant chemotherapy and/or radiotherapy.